Alumis Inc. (ALMS) vs Design Therapeutics, Inc. (DSGN)
A side-by-side comparison of Alumis Inc. and Design Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMS
Alumis Inc.
$6.84HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
DSGN
Design Therapeutics, Inc.
$12.42HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALMS vs DSGN
growth of $100 · dividends reinvested · last 2yALMS -48.6% (-28.3%/yr)DSGN +270.7% (+92.5%/yr)DSGN compounded faster over this window
Log scale — wide-divergence pair
ALMS DSGN
ALMS vs DSGN: by the numbers
- •ALMS is the larger company ($844M vs $776M market cap).
- •Both run net losses; DSGN's is the smaller (0.00% vs -5933.45% net margin).
Metrics side by side
Valuation
| Metric | ALMS | DSGN |
|---|---|---|
| P/S ratio | 114.12 | N/A |
| P/B ratio | 1.87 | 3.84 |
Profitability
| Metric | ALMS | DSGN |
|---|---|---|
| Gross margin | 88.23% | 0.00% |
| Operating margin | -1776.32% | 0.00% |
| Net margin | -5933.45% | 0.00% |
| ROE | -97.08% | -35.07% |
| ROIC | -94.76% | -38.92% |
Growth (annualized)
| Metric | ALMS | DSGN |
|---|---|---|
| Total return CAGR (5Y) | N/A | -3.82% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.